GRHL2 and neoplasm: To verify this previously unknown cell-of-origin for pRCC, we recruited an independent pRCC cohort of 50 patients from Drum Tower hospital (Supplementary Fig. 1b) and performed immunofluorescence staining with the PT marker AQP1, the CD_PC marker GATA3 or GRHL2, on tumor samples from these patients.